Germany In-Vitro Diagnostics Market 2030 Growth Analysis

Name: Germany In-Vitro Diagnostics Market 2030 Growth Analysis
Creator: Next Move Strategy Consulting
Published: 2025-10-04T20:00:00-04:00
License: https://www.nextmsc.com/privacy-policy

About Report

Download Now

Germany In-Vitro Diagnostic Market By Product & Service (Reagents & Consumables, Instruments & Devices, and Software & Services), By Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, and Others), By Testing Site/Channel (Central & Reference Laboratories, Hospital & Physician Labs, Point-of-Care & Retail, and Others), By Application (Infectious Diseases, Oncology, Cardiovascular Health, and Others) – Opportunity Analysis and Industry Forecast, 2024–2030.

Download PDF

Speak to Our Analyst

Germany In-Vitro Diagnostics Market Overview

The Germany In-Vitro Diagnostics Market size was valued at USD 3.01 billion in 2023, and is predicted to reach USD 3.46 billion by 2030, at a CAGR of 1.6% from 2024 to 2030. In-Vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Rising Healthcare Expenditure in Germany Drives In-Vitro Diagnostics Market Growth

The substantial healthcare expenditure is significant in propelling the growth of the in-vitro diagnostics market in this region. Germany allocates substantial resources towards improving healthcare infrastructure, enhancing medical facilities, and expanding access to healthcare services, including diagnostic testing. Germany's health expenditure per capita stands at USD 8011, surpassing the OECD average of USD 4986. This accounts for 12.7% of the country's GDP, notably higher than the OECD average of 9.2%. This increased investment enables healthcare facilities to adopt innovative in-vitro diagnostics products and platforms offering more accurate, efficient, and timely diagnostic capabilities.

Product Approvals and Collaborations Drive Growth in In-Vitro Diagnostics Market in Germany

The expansion of product approvals and certifications, coupled with increased collaboration among leading companies throughout the nation, drives the growth of the in-vitro diagnostics market. For instance, in June 2022, Spindiag GmbH, a Germany-based medical technology company, obtained CE- In-Vitro diagnostics marks for two of its latest Rhonda rapid polymerase chain reaction (PCR) tests designed for point-of-care use. Spindiag's Rhonda Respi test delivers rapid results within an hour from a single swab, accurately distinguishing between infections caused by SARS-CoV-2, Influenza A/B, and respiratory syncytial virus.

Additionally, Spindiag's MRSA test has obtained CE- in-vitro diagnostics certification, affirming its adherence to standards for in-vitro diagnostic medical devices, ensuring reliability and clinical accuracy. Furthermore, in April 2024, Robert Bosch GmbH partnered with R-Biopharm AG on investing USD 160.1 million to enhance the Vivalytic molecular diagnostic platform. Their goal is to develop new PCR tests, including for multi-resistant bacteria, using Bosch's BioMEMS technology. This collaboration aims to streamline diagnostics, making point-of-care testing more accessible and efficient.

High Research, Development, and Regulatory Approval Costs Hinder Vitro Diagnostics Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the in-vitro diagnostics market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

Point-of-care testing (POCT) is poised to be a significant driver of growth in the in-vitro diagnostics (IVD) market in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions. By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Competitive Landscape

The promising players operating in the Germany in-vitro diagnostics industry include Biomerieux, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc, Becton, Dickinson and Company, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc,Abbott Laboratories, Qiagen N.V., Intertek Group plc, Stevanato Group, Charles River Laboratories, Cyient, FUJIFILM Corporation, Seegene Inc., and others.

Germany In-Vitro Diagnostic Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

Key Players

Biomerieux
F. Hoffmann-La Roche Ltd
Bio-Rad Laboratories, Inc
Becton, Dickinson and Company
Siemens Healthineers AG
Sysmex Corporation
Thermo Fisher Scientific Inc
Abbott Laboratories
Qiagen N.V.
Intertek Group plc
Stevanato Group
Charles River Laboratories
Cyient
FUJIFILM Corporation
Seegene Inc.

Report Scope and Segmentation

Parameters	Details
Market Size Value in 2023	USD 3.01 billion
Revenue Forecast in 2030	USD 3.46 billion
Value Growth Rate	CAGR of 1.6% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Rising Healthcare Expenditure in Germany Drives In-Vitro Diagnostics Market Growth. Product Approvals and Collaborations Drive Growth in In-Vitro Diagnostics Market in Germany.
Companies Profiled	15
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

About the Author

Jayanta Das is a senior research analyst delivering high-impact market intelligence across global markets. He leads comprehensive studies covering market assessment, forecasting, competitive evaluation, regulatory review, and trend analysis. Known for his structured and methodical approach, Jayanta excels at converting complex datasets into clear, decision-ready insights for leadership teams. His work supports strategic planning through credible sourcing, analytical precision, strong validation frameworks, and well-structured, business-focused reporting that enables confident decision-making.

About the Reviewer

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2024 - 2030, BILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2024

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 RISING HEALTHCARE EXPENDITURE IN GERMANY DRIVES IN-VITRO DIAGNOSTICS MARKET GROWTH
  2. 5.1.2 PRODUCT APPROVALS AND COLLABORATIONS DRIVE GROWTH IN IN-VITRO DIAGNOSTICS MARKET IN GERMANY
3. 5.2 CHALLENGES
4. 1. 5.2.1 HIGH RESEARCH, DEVELOPMENT, AND REGULATORY APPROVAL COSTS HINDER VITRO DIAGNOSTICS MARKET GROWTH
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 INTRODUCTION OF POINT-OF-CARE TESTING SOLUTIONS IN IVD CREATES OPPORTUNITY

1. 6.1 OVERVIEW
2. 6.2 REAGENTS MARKET
3. 6.3 INSTRUMENTS MARKET
4. 6.4 SOFTWARE AND SERVICES MARKET

1. 7.1 OVERVIEW
2. 7.2 IMMUNODIAGNOSTICS MARKET
3. 1. 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
  2. 7.2.2 RAPID TESTS
  3. 7.2.3 CHEMILUMINESCENCE IMMUNOASSAY (CLIA)
  4. 7.2.4 ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT)
  5. 7.2.5 RADIOIMMUNOASSAY (RIA)
  6. 7.2.6 WESTERN BLOT
4. 7.3 HEMATOLOGY MARKET
5. 7.4 MOLECULAR DIAGNOSTICS MARKET
6. 1. 7.4.1 PCR
  2. 1. 7.4.1.1 MONOPLEX PCR
    2. 7.4.1.2 MULTIPLEX PCR
  3. 7.4.2 INAAT
  4. 7.4.3 HYBRIDIZATION
  5. 7.4.4 DNA DIAGNOSTICS
  6. 7.4.5 MICROARRAY
  7. 7.4.6 OTHER MOLECULAR DIAGNOSTICS
7. 7.5 TISSUE DISGNOSTICS MARKET
8. 7.6 CLINICAL CHEMISTRY MARKET
9. 1. 7.6.1 BASIC METABOLIC PANEL
  2. 7.6.2 LIVER PANEL
  3. 7.6.3 RENAL PROFILE
  4. 7.6.4 LIPID PROFILE
  5. 7.6.5 THYROID FUNCTION PANEL
  6. 7.6.6 ELECTROLYTE PANEL
  7. 7.6.7 SPECIALITY CHEMICALS
10. 7.7 OTHER IVD TECHNIQUES MARKET

1. 8.1 OVERVIEW
2. 8.2 INFECTIOUS DISEASES MARKET
3. 8.3 CANCER MARKET
4. 8.4 CARDIAC DISEASES MARKET
5. 8.5 IMMUNE SYSTEM DISORDERS MARKET
6. 8.6 NEPHROLOGICAL DISEASES MARKET
7. 8.7 GASTROINTESTINAL DISEASES MARKET
8. 8.8 OTHER INDICATIONS MARKET

1. 9.1 OVERVIEW
2. 9.2 STAND ALONE LABORATORY MARKET
3. 9.3 HOSPITALS MARKET
4. 9.4 ACADEMICS AND MEDICAL SCHOOLS MARKET
5. 9.5 POINT OF CARE TESTING MARKET
6. 9.6 OTHER END-USERS MARKET

1. 10.1 BIOMERIEUX
2. 1. 10.1.1 COMPANY OVERVIEW
  2. 10.1.2 COMPANY SNAPSHOT
  3. 10.1.3 OPERATING BUSINESS SEGMENTS
  4. 10.1.4 PRODUCT PORTFOLIO
  5. 10.1.5 BUSINESS PERFORMANCE
  6. 10.1.6 BUSINESS SEGMENTS
  7. 10.1.7 GEOGRAPHIC SEGMENTS
  8. 10.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.1.9 PRIMARY MARKET COMPETITORS
3. 10.2 F. HOFFMANN-LA ROCHE LTD
4. 1. 10.2.1 COMPANY OVERVIEW
  2. 10.2.2 COMPANY SNAPSHOT
  3. 10.2.3 OPERATING BUSINESS SEGMENTS
  4. 10.2.4 PRODUCT PORTFOLIO
  5. 10.2.5 BUSINESS PERFORMANCE
  6. 10.2.6 BUSINESS SEGMENTS
  7. 10.2.7 GEOGRAPHIC SEGMENTS
  8. 10.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.2.9 PRIMARY MARKET COMPETITORS
5. 10.3 BIO-RAD LABORATORIES, INC
6. 1. 10.3.1 COMPANY OVERVIEW
  2. 10.3.2 COMPANY SNAPSHOT
  3. 10.3.3 OPERATING BUSINESS SEGMENTS
  4. 10.3.4 PRODUCT PORTFOLIO
  5. 10.3.5 BUSINESS PERFORMANCE
  6. 10.3.6 BUSINESS SEGMENTS
  7. 10.3.7 GEOGRAPHIC SEGMENTS
  8. 10.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.3.9 PRIMARY MARKET COMPETITORS
7. 10.4 BECTON, DICKINSON AND COMPANY
8. 1. 10.4.1 COMPANY OVERVIEW
  2. 10.4.2 COMPANY SNAPSHOT
  3. 10.4.3 OPERATING BUSINESS SEGMENTS
  4. 10.4.4 PRODUCT PORTFOLIO
  5. 10.4.5 BUSINESS PERFORMANCE
  6. 10.4.6 BUSINESS SEGMENTS
  7. 10.4.7 GEOGRAPHIC SEGMENTS
  8. 10.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.4.9 PRIMARY MARKET COMPETITORS
9. 10.5 SIEMENS HEALTHINEERS AG
10. 1. 10.5.1 COMPANY OVERVIEW
  2. 10.5.2 COMPANY SNAPSHOT
  3. 10.5.3 OPERATING BUSINESS SEGMENTS
  4. 10.5.4 PRODUCT PORTFOLIO
  5. 10.5.5 BUSINESS PERFORMANCE
  6. 10.5.6 BUSINESS SEGMENTS
  7. 10.5.7 GEOGRAPHIC SEGMENTS
  8. 10.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.5.9 PRIMARY MARKET COMPETITORS
11. 10.6 SYSMEX CORPORATION
12. 1. 10.6.1 COMPANY OVERVIEW
  2. 10.6.2 COMPANY SNAPSHOT
  3. 10.6.3 OPERATING BUSINESS SEGMENTS
  4. 10.6.4 PRODUCT PORTFOLIO
  5. 10.6.5 BUSINESS PERFORMANCE
  6. 10.6.6 BUSINESS SEGMENTS
  7. 10.6.7 GEOGRAPHIC SEGMENTS
  8. 10.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.6.9 PRIMARY MARKET COMPETITORS
13. 10.7 THERMO FISHER SCIENTIFIC INC
14. 1. 10.7.1 COMPANY OVERVIEW
  2. 10.7.2 COMPANY SNAPSHOT
  3. 10.7.3 OPERATING BUSINESS SEGMENTS
  4. 10.7.4 PRODUCT PORTFOLIO
  5. 10.7.5 BUSINESS PERFORMANCE
  6. 10.7.6 BUSINESS SEGMENTS
  7. 10.7.7 GEOGRAPHIC SEGMENTS
  8. 10.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.7.9 PRIMARY MARKET COMPETITORS
15. 10.8 ABBOTT LABORATORIES
16. 1. 10.8.1 COMPANY OVERVIEW
  2. 10.8.2 COMPANY SNAPSHOT
  3. 10.8.3 OPERATING BUSINESS SEGMENTS
  4. 10.8.4 PRODUCT PORTFOLIO
  5. 10.8.5 BUSINESS PERFORMANCE
  6. 10.8.6 BUSINESS SEGMENTS
  7. 10.8.7 GEOGRAPHIC SEGMENTS
  8. 10.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.8.9 PRIMARY MARKET COMPETITORS
17. 10.9 QIAGEN N.V.
18. 1. 10.9.1 COMPANY OVERVIEW
  2. 10.9.2 COMPANY SNAPSHOT
  3. 10.9.3 OPERATING BUSINESS SEGMENTS
  4. 10.9.4 PRODUCT PORTFOLIO
  5. 10.9.5 BUSINESS PERFORMANCE
  6. 10.9.6 BUSINESS SEGMENTS
  7. 10.9.7 GEOGRAPHIC SEGMENTS
  8. 10.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.9.9 PRIMARY MARKET COMPETITORS
19. 10.10 INTERTEK GROUP PLC
20. 1. 10.10.1 COMPANY OVERVIEW
  2. 10.10.2 COMPANY SNAPSHOT
  3. 10.10.3 OPERATING BUSINESS SEGMENTS
  4. 10.10.4 PRODUCT PORTFOLIO
  5. 10.10.5 BUSINESS PERFORMANCE
  6. 10.10.6 BUSINESS SEGMENTS
  7. 10.10.7 GEOGRAPHIC SEGMENTS
  8. 10.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.10.9 PRIMARY MARKET COMPETITORS
21. 10.11 STEVANATO GROUP
22. 1. 10.11.1 COMPANY OVERVIEW
  2. 10.11.2 COMPANY SNAPSHOT
  3. 10.11.3 OPERATING BUSINESS SEGMENTS
  4. 10.11.4 PRODUCT PORTFOLIO
  5. 10.11.5 BUSINESS PERFORMANCE
  6. 10.11.6 BUSINESS SEGMENTS
  7. 10.11.7 GEOGRAPHIC SEGMENTS
  8. 10.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.11.9 PRIMARY MARKET COMPETITORS
23. 10.12 CHARLES RIVER LABORATORIES
24. 1. 10.12.1 COMPANY OVERVIEW
  2. 10.12.2 COMPANY SNAPSHOT
  3. 10.12.3 OPERATING BUSINESS SEGMENTS
  4. 10.12.4 PRODUCT PORTFOLIO
  5. 10.12.5 BUSINESS PERFORMANCE
  6. 10.12.6 BUSINESS SEGMENTS
  7. 10.12.7 GEOGRAPHIC SEGMENTS
  8. 10.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.12.9 PRIMARY MARKET COMPETITORS
25. 10.13 CYIENT
26. 1. 10.13.1 COMPANY OVERVIEW
  2. 10.13.2 COMPANY SNAPSHOT
  3. 10.13.3 OPERATING BUSINESS SEGMENTS
  4. 10.13.4 PRODUCT PORTFOLIO
  5. 10.13.5 BUSINESS PERFORMANCE
  6. 10.13.6 BUSINESS SEGMENTS
  7. 10.13.7 GEOGRAPHIC SEGMENTS
  8. 10.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.13.9 PRIMARY MARKET COMPETITORS
27. 10.14 FUJIFILM CORPORATION
28. 1. 10.14.1 COMPANY OVERVIEW
  2. 10.14.2 COMPANY SNAPSHOT
  3. 10.14.3 OPERATING BUSINESS SEGMENTS
  4. 10.14.4 PRODUCT PORTFOLIO
  5. 10.14.5 BUSINESS PERFORMANCE
  6. 10.14.6 BUSINESS SEGMENTS
  7. 10.14.7 GEOGRAPHIC SEGMENTS
  8. 10.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.14.9 PRIMARY MARKET COMPETITORS
29. 10.15 SEEGENE INC.
30. 1. 10.15.1 COMPANY OVERVIEW
  2. 10.15.2 COMPANY SNAPSHOT
  3. 10.15.3 OPERATING BUSINESS SEGMENTS
  4. 10.15.4 PRODUCT PORTFOLIO
  5. 10.15.5 BUSINESS PERFORMANCE
  6. 10.15.6 BUSINESS SEGMENTS
  7. 10.15.7 GEOGRAPHIC SEGMENTS
  8. 10.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. GERMANY IN VITRO DIAGONOSTIC MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 2. REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 3. INSTRUMENTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 4. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 5. GERMANY IN VITRO DIAGONOSTIC MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 6. IMMUNODIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 7. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 8. RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 9. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 10. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 11. RADIOIMMUNOASSAY (RIA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 12. WESTERN BLOT, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 13. HEMATOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 14. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 15. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 16. INAAT, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 17. HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 18. DNA DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 19. MICROARRAY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 20. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 21. TISSUE DISGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 22. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 23. BASIC METABOLIC PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 24. LIVER PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 25. RENAL PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 26. LIPID PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 27. THYROID FUNCTION PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 28. ELECTROLYTE PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 29. SPECIALITY CHEMICALS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 31. GERMANY IN VITRO DIAGONOSTIC MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 32. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 33. CANCER, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 34. CARDIAC DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 38. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 39. GERMANY IN VITRO DIAGONOSTIC MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 41. HOSPITALS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 43. POINT OF CARE TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 44. OTHER END-USERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 45. BIOMERIEUX: COMPANY SNAPSHOT
TABLE 46. BIOMERIEUX: OPERATING BUSINESS SEGMENTS
TABLE 47. BIOMERIEUX: PRODUCT PORTFOLIO
TABLE 48. BIOMERIEUX: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 49. BIOMERIEUX: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 50. BIOMERIEUX: KEY STRATERGY
TABLE 51. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 52. F. HOFFMANN-LA ROCHE LTD: OPERATING BUSINESS SEGMENTS
TABLE 53. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 54. F. HOFFMANN-LA ROCHE LTD: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 55. F. HOFFMANN-LA ROCHE LTD: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 56. F. HOFFMANN-LA ROCHE LTD: KEY STRATERGY
TABLE 57. BIO-RAD LABORATORIES, INC: COMPANY SNAPSHOT
TABLE 58. BIO-RAD LABORATORIES, INC: OPERATING BUSINESS SEGMENTS
TABLE 59. BIO-RAD LABORATORIES, INC: PRODUCT PORTFOLIO
TABLE 60. BIO-RAD LABORATORIES, INC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 61. BIO-RAD LABORATORIES, INC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 62. BIO-RAD LABORATORIES, INC: KEY STRATERGY
TABLE 63. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 64. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 65. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 66. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 67. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 68. BECTON, DICKINSON AND COMPANY: KEY STRATERGY
TABLE 69. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 70. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 71. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 72. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 73. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 74. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 75. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 76. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 77. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 78. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 79. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 80. SYSMEX CORPORATION: KEY STRATERGY
TABLE 81. THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
TABLE 82. THERMO FISHER SCIENTIFIC INC: OPERATING BUSINESS SEGMENTS
TABLE 83. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 84. THERMO FISHER SCIENTIFIC INC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 85. THERMO FISHER SCIENTIFIC INC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 86. THERMO FISHER SCIENTIFIC INC: KEY STRATERGY
TABLE 87. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 88. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 89. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 90. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 91. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 92. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 93. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 94. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS
TABLE 95. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 96. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 97. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 98. QIAGEN N.V.: KEY STRATERGY
TABLE 99. INTERTEK GROUP PLC: COMPANY SNAPSHOT
TABLE 100. INTERTEK GROUP PLC: OPERATING BUSINESS SEGMENTS
TABLE 101. INTERTEK GROUP PLC: PRODUCT PORTFOLIO
TABLE 102. INTERTEK GROUP PLC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 103. INTERTEK GROUP PLC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 104. INTERTEK GROUP PLC: KEY STRATERGY
TABLE 105. STEVANATO GROUP: COMPANY SNAPSHOT
TABLE 106. STEVANATO GROUP: OPERATING BUSINESS SEGMENTS
TABLE 107. STEVANATO GROUP: PRODUCT PORTFOLIO
TABLE 108. STEVANATO GROUP: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 109. STEVANATO GROUP: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 110. STEVANATO GROUP: KEY STRATERGY
TABLE 111. CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 112. CHARLES RIVER LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 113. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
TABLE 114. CHARLES RIVER LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 115. CHARLES RIVER LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 116. CHARLES RIVER LABORATORIES: KEY STRATERGY
TABLE 117. CYIENT: COMPANY SNAPSHOT
TABLE 118. CYIENT: OPERATING BUSINESS SEGMENTS
TABLE 119. CYIENT: PRODUCT PORTFOLIO
TABLE 120. CYIENT: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 121. CYIENT: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 122. CYIENT: KEY STRATERGY
TABLE 123. FUJIFILM CORPORATION: COMPANY SNAPSHOT
TABLE 124. FUJIFILM CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 125. FUJIFILM CORPORATION: PRODUCT PORTFOLIO
TABLE 126. FUJIFILM CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 127. FUJIFILM CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 128. FUJIFILM CORPORATION: KEY STRATERGY
TABLE 129. SEEGENE INC.: COMPANY SNAPSHOT
TABLE 130. SEEGENE INC.: OPERATING BUSINESS SEGMENTS
TABLE 131. SEEGENE INC.: PRODUCT PORTFOLIO
TABLE 132. SEEGENE INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 133. SEEGENE INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 134. SEEGENE INC.: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. GERMANY IN VITRO DIAGONOSTIC MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
FIGURE 7. REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 8. INSTRUMENTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 9. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 10. GERMANY IN VITRO DIAGONOSTIC MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
FIGURE 11. IMMUNODIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 12. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 13. RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 14. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 15. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 16. RADIOIMMUNOASSAY (RIA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 17. WESTERN BLOT, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 18. HEMATOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 19. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 20. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 21. INAAT, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 22. HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 23. DNA DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 24. MICROARRAY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 25. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 26. TISSUE DISGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 27. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 28. BASIC METABOLIC PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 29. LIVER PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 30. RENAL PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 31. LIPID PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 32. THYROID FUNCTION PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 33. ELECTROLYTE PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 34. SPECIALITY CHEMICALS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 36. GERMANY IN VITRO DIAGONOSTIC MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
FIGURE 37. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 38. CANCER, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 39. CARDIAC DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 43. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 44. GERMANY IN VITRO DIAGONOSTIC MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 46. HOSPITALS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 49. OTHER END-USERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 50. BIOMERIEUX: NET SALES, (2022-2024)
FIGURE 51. BIOMERIEUX: PRIMARY MARKET COMPETITORS
FIGURE 52. F. HOFFMANN-LA ROCHE LTD: NET SALES, (2022-2024)
FIGURE 53. F. HOFFMANN-LA ROCHE LTD: PRIMARY MARKET COMPETITORS
FIGURE 54. BIO-RAD LABORATORIES, INC: NET SALES, (2022-2024)
FIGURE 55. BIO-RAD LABORATORIES, INC: PRIMARY MARKET COMPETITORS
FIGURE 56. BECTON, DICKINSON AND COMPANY: NET SALES, (2022-2024)
FIGURE 57. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS
FIGURE 58. SIEMENS HEALTHINEERS AG: NET SALES, (2022-2024)
FIGURE 59. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 60. SYSMEX CORPORATION: NET SALES, (2022-2024)
FIGURE 61. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 62. THERMO FISHER SCIENTIFIC INC: NET SALES, (2022-2024)
FIGURE 63. THERMO FISHER SCIENTIFIC INC: PRIMARY MARKET COMPETITORS
FIGURE 64. ABBOTT LABORATORIES: NET SALES, (2022-2024)
FIGURE 65. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 66. QIAGEN N.V.: NET SALES, (2022-2024)
FIGURE 67. QIAGEN N.V.: PRIMARY MARKET COMPETITORS
FIGURE 68. INTERTEK GROUP PLC: NET SALES, (2022-2024)
FIGURE 69. INTERTEK GROUP PLC: PRIMARY MARKET COMPETITORS
FIGURE 70. STEVANATO GROUP: NET SALES, (2022-2024)
FIGURE 71. STEVANATO GROUP: PRIMARY MARKET COMPETITORS
FIGURE 72. CHARLES RIVER LABORATORIES: NET SALES, (2022-2024)
FIGURE 73. CHARLES RIVER LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 74. CYIENT: NET SALES, (2022-2024)
FIGURE 75. CYIENT: PRIMARY MARKET COMPETITORS
FIGURE 76. FUJIFILM CORPORATION: NET SALES, (2022-2024)
FIGURE 77. FUJIFILM CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 78. SEEGENE INC.: NET SALES, (2022-2024)
FIGURE 79. SEEGENE INC.: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Download Free Sample

Full Name *

Please Enter Full Name

Business Email Id *

Please Enter Valid Email ID

Phone Number *

Please enter Country Code and Phone No

Message

Please enter message

Yes, I have read the Privacy Policy

Frequently Asked Questions

The Germany in-vitro diagnostics market is estimated to reach USD 3.46 billion by 2030.

The key players in the Germany in-vitro diagnostics market include Biomerieux, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc, Becton, Dickinson and Company, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc,Abbott Laboratories, Qiagen N.V., Intertek Group plc, Stevanato Group, Charles River Laboratories, Cyient, FUJIFILM Corporation, Seegene Inc., and others.

The Germany in-vitro diagnostics market was estimate to reach USD 3.01 billion in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the market growth.

Introduction of Point-of-Care Testing Solutions creates opportunities for the in-vitro diagnostics in the coming future.

Purchase Options Flash
sale

Multi User

$3,217 $4595

Single User

$2,517 $3595

Enterprise

$4,617 $6595

Datapack

$1,467 $2095

Download Sample

Inquire Before Buying

Speak to Our Analyst

Share with Peers

Request Sample